GemCap Biotech ApS: Financial statements 2020
CVR: 38189174
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
GemCap Biotech ApS (CVR 38189174) has filed annual accounts for 2020. In 2020, the company reported a net result of EUR 0 compared with EUR 0 the year before. Equity in the 2020 report amounted to EUR 6,750. The solvency ratio was 100%.
- Profit/Loss
- EUR 0
- Equity
- EUR 6,750
- Total Assets
- EUR 6,750
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | - | 0 EUR | 7 t. EUR | - |
| 2019 | - | - | 0 EUR | 7 t. EUR | - |
| 2018 | - | - | 0 EUR | 7 t. EUR | - |
Official annual report
How creditworthy is GemCap Biotech ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
GemCap Biotech ApS has published its annual report for 2019. The net result was DKK 0.
As of May 28, 2020, Werner Schmidt has left the board of directors of GemCap Biotech ApS.
As of January 27, 2020, Werner Schmidt has joined the board of directors of GemCap Biotech ApS.
As of January 27, 2020, Werner Ernst Spiegler has left the board of directors of GemCap Biotech ApS.
About GemCap Biotech ApS
GemCap Biotech ApS was a Danish company of the type Anpartsselskab based in Kongens Lyngby, founded in 2016. The company has been dissolved on 24 March 2024. The company was registered under the industry Anden finansiel formidling undtagen forsikring og pensionsforsikring, i.a.n.. According to the 2023 annual report, the company had an average of 0 employees. In 2023, the company reported a net result of EUR 0 compared with EUR 0 the year before. Equity in the 2023 report amounted to EUR 27,000.